Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Degenerative cervical myelopathy is the most common form of non-traumatic spinal cord injury. This multicentre, double-blind, placebo-controlled, randomized, phase 3 trial was done at 16 university-affiliated centers. There was no difference between the riluzole and placebo groups in the primary endpoint of change in mJOA score at 6-month follow-up.
